Literature DB >> 20362232

JAK2 V617F-positive essential thrombocythemia in a patient with Klinefelter syndrome: a case report.

Ho-Young Yhim1, Hee Sun Kim, Ji-Youn Sohn, Min-Ju Song, Na-Ri Lee, Eun-Kee Song, Sam-Im Choi, Chang-Yeol Yim, Jae-Yong Kwak.   

Abstract

Klinefelter syndrome (KS) is the most commonly diagnosed X chromosome aneuploid syndrome among males. The association between hematologic malignancies such as non-Hodgkin lymphoma and leukemia and KS has been established recently on the basis of numerous case reports and a large cohort study. The risk of chronic myeloproliferative disease (MPD) as a hematologic malignancy in KS, however, has not been evaluated to date. Moreover, to our knowledge, there is only one case report that observed MPD in a patient with KS. Even though the Janus kinase 2 (JAK2) mutation was considered the primary cause in the pathogenesis of MPD, the mutation status was not described in that report. We found JAK2 V617F mutation-positive essential thromobocythemia (ET) in a patient with KS. To the best of our knowledge, this case represents the first case report of JAK2 V617F mutation in a patient with KS. Furthermore, we also suggest the hypothesis that X chromosome aneuploidy as a "pre-JAK2" cytogenetic change may be associated with the development of clonal hematopoiesis and carcinogenesis, because of the finding of higher oncogenic potential of extra X chromosome. In this study, we present the first report of JAK2 V617F-positive ET in a patient with KS, as well as a review of the relevant literature. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20362232     DOI: 10.1016/j.cancergencyto.2010.01.001

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  1 in total

1.  Extra X chromosome in mosaic Klinefelter syndrome is associated with a hematologic malignancy.

Authors:  Mi-Ae Jang; Chul Won Jung; Chul Won Jung
Journal:  Ann Lab Med       Date:  2013-06-24       Impact factor: 3.464

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.